# India Neurodegenerative Disease Market

> India Neurodegenerative Disease Market Research Report By Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's Disease), By Diagnosis Method (Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, Electrophysiological Tests), By Treatment Type (Medication, Therapy, Rehabilitation, Surgical Interventions) and By Route of Administration (Oral, Injectable, Intravenous, Transdermal) -Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.6%
- **2024:** $ 4,096.32 Million
- **2025:** $ 4,407.64 Million
- **2035:** $ 9,171 Million
- **Key Players:** Biogen (US), Eli Lilly (US), Roche (CH), Novartis (CH), AstraZeneca (GB), Merck (US), Amgen (US), Sanofi (FR), Bristol-Myers Squibb (US)

**Report ID:** MRFR/MED/50858-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-neurodegenerative-disease-market-52617

---

## Market Summary

## **India Neurodegenerative Disease Market Overview**

As per MRFR analysis, the India Neurodegenerative Disease Market Size was estimated at 1.1 (USD Billion) in 2023. The India Neurodegenerative Disease Market Industry is expected to grow from 1.5(USD Billion) in 2024 to 4 (USD Billion) by 2035. The India Neurodegenerative Disease Market CAGR (growth rate) is expected to be around 9.326% during the forecast period (2025 - 2035).

**Key India Neurodegenerative Disease Market Trends Highlighted**

The India Neurodegenerative Disease Market is currently experiencing significant growth driven by several key market drivers. An increasing aging population in India is one of the primary factors, as older adults are more susceptible to neurodegenerative diseases such as Alzheimer's and Parkinson's. The rise in lifestyle-related risk factors, coupled with advancements in neuroimaging and biomarker technologies, is enhancing disease detection and diagnostic capabilities, contributing to market growth. Additionally, the Indian government has been actively promoting healthcare initiatives, focusing on improving mental health infrastructure and supporting research in neurodegenerative conditions.

Opportunities in the India Neurodegenerative Disease Market are vast, especially in the realm of drug development and therapeutic interventions. With a growing demand for innovative treatment options, there is room for the introduction of newer drugs and personalized medicine approaches. Collaborative efforts between the public and private sectors can enhance research and development, fostering an environment conducive to healthcare advancements. The increasing awareness of mental health and neurodegenerative disorders also presents a chance for educational campaigns to promote early diagnosis and treatment options.

Trends in recent times show that there is a shift toward digital health solutions, including telemedicine and mobile health applications, to manage neurodegenerative diseases more effectively. These technologies provide better access to specialists and facilitate ongoing care, particularly in rural areas where healthcare services may be limited. Furthermore, there is a growing emphasis on patient-centric care, where treatment plans are tailored to individual needs based on the distinct nature of various neurodegenerative diseases. Overall, the combination of these trends and the evolving healthcare landscape points towards a promising future for the neurodegenerative disease market in India.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**India Neurodegenerative Disease Market Drivers**

**Increasing Prevalence of Neurodegenerative Diseases**

The rising frequency of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease in India is a major driving force in the India Neurodegenerative Disease Market. According to the Ministry of Health and Family Welfare, Alzheimer's disease is predicted to affect around 4.7 million people in India in recent years. Furthermore, recorded instances have increased by 20% in the previous decade, which might be ascribed to the country's aging population and rising life expectancy.

According to research from the Indian Council of Medical Research, the number of people aged 60 and older would reach almost 300 million by 2050, increasing the demand for effective neurodegenerative disease treatments and supportive services. This rising patient population demands ongoing research and development (R&D) by pharmaceutical firms such as Sun Pharmaceutical Industries Limited, which invests substantially in creating new medicines suited to specific illnesses. As the number of patients grows, so does the demand for novel therapies, boosting the India Neurodegenerative Disease Market.

**Enhancements in Healthcare Infrastructure**

The ongoing enhancements in healthcare infrastructure across India are propelling the growth of the India Neurodegenerative Disease Market Industry. With initiatives like the Ayushman Bharat scheme, which aims to provide health insurance coverage to over 500 million underprivileged citizens, there is improved access to healthcare facilities and treatments for neurodegenerative diseases.

The Government of India has allocated substantial funds to improve hospital facilities and increase the number of neurological specialists, resulting in an augmented capacity to diagnose and treat these disorders.According to the National Health Authority, there was a 15% increase in the setup of specialized neurology centers between 2018 and 2021, allowing for better patient management and care. This investment in infrastructure facilitates timely diagnosis and effective management of neurodegenerative diseases, further stimulating the market.

**Advancements in Therapeutics and Research**

Research and Development efforts in the field of neurodegenerative diseases are rapidly advancing, bolstered by both public and private sector investments. The Government of India, through its National Bio-Pharma Mission, is investing significantly to promote biopharmaceutical innovations in the country, with a priority on progressive technologies for the treatment of neurodegenerative conditions.

Establishments such as the Institute of Neuroscience in Kolkata are at the forefront of ground-breaking research, focusing on novel therapies that show promise in combating the effects of these diseases.The increase in collaborations between domestic and international entities, as reported by the Department of Biotechnology in India, has observed a 25% rise in joint clinical trials for neurological therapies over the past five years. Such advancements are critical for addressing the high unmet medical needs in this area, thereby driving the growth of the India Neurodegenerative Disease Market.

**India Neurodegenerative Disease Market Segment Insights**

**Neurodegenerative Disease Market Disease Type Insights**

The India Neurodegenerative Disease Market, particularly in the context of Disease Type, highlights a diversity of debilitating conditions that significantly impact the population. Alzheimer's Disease remains a crucial area of focus, emerging as one of the leading causes of cognitive decline among elderly patients, thereby placing a considerable burden on caregivers and healthcare services.

Meanwhile, Parkinson's Disease is notable for its contribution to motor dysfunction and quality of life challenges faced by individuals, necessitating targeted therapeutic strategies and ongoing Research and Development initiatives.In parallel, Multiple Sclerosis has attracted attention due to its complex pathophysiology and episodic nature, resulting in a need for innovative treatment approaches tailored to the fluctuating symptoms experienced by patients. Moreover, Amyotrophic Lateral Sclerosis presents unique challenges due to its rapid progression and impact on neuro-motor functions, requiring a multifaceted approach that includes palliative care and advanced therapeutics.

Huntington's Disease, with its genetic basis, underscores the importance of early diagnosis and long-term management plans aimed at improving patient outcomes.As the Indian population ages and lifestyle factors evolve, the prevalence and awareness of these disorders rise, compelling stakeholders to develop strategies that address the growing healthcare demands associated with these neurodegenerative diseases. Trends in technology and personalized medicine offer promising avenues for the management and treatment of these conditions, paving the way for improved life quality among affected individuals.

The ongoing collaboration between government initiatives and healthcare sectors aims to bolster support systems, research initiatives, and public health campaigns focused on awareness and accessibility.In examining the India Neurodegenerative Disease Market, it becomes evident that the landscape is rapidly evolving, driven by a combination of demographic shifts, advancements in medical technology, and an increasing acknowledgment of the importance of mental health alongside physical well-being. As such, addressing neurodegenerative diseases within this market presents significant opportunities for stakeholders keen on making impactful contributions to the healthcare sector in India.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Neurodegenerative Disease Market Diagnosis Method Insights**

The Diagnosis Method segment within the India Neurodegenerative Disease Market plays a crucial role in accurately identifying and managing neurodegenerative disorders.

This segment encompasses various methods including Neurological Examination, which serves as the foundational step in assessing patients’ neurological health through clinical evaluations; Imaging Techniques that are pivotal in visualizing brain abnormalities, facilitating early detection of conditions like Alzheimer's and Parkinson's diseases; Cerebrospinal Fluid Analysis, which provides critical insights into the biochemical markers in the fluid surrounding the brain and spinal cord, thereby aiding in the diagnosis of various neurodegenerative diseases; and Electrophysiological Tests, which evaluate the electrical activity of the brain and nerves, thus contributing valuable information for diagnosing conditions such as multiple sclerosis.Each method serves a unique purpose, catering to different aspects of neurodegenerative diseases and collectively enhancing diagnostic accuracy and patient management in India.

The increasing prevalence of these diseases, along with advancements in diagnostic technologies, drives the need for sophisticated methods, highlighting the importance of this segment in the broader context of the India Neurodegenerative Disease Market. Effective diagnosis not only aids in timely medical intervention but also significantly contributes to improving the quality of life for affected individuals.

**Neurodegenerative Disease Market Treatment Type Insights**

The Treatment Type segment of the India Neurodegenerative Disease Market is crucial in addressing various neurological conditions affecting a significant population. Medication often serves as the foundation of treatment, focusing on alleviating symptoms and improving quality of life, which is vital for patients dealing with chronic conditions. Therapy plays an essential role by offering psychological support and cognitive rehabilitation, enhancing patients' functional abilities and emotional well-being.

Another significant aspect is Rehabilitation, which encompasses a range of services to help individuals recover lost skills or adapt to disabilities, underscoring the importance of tailored treatment plans in fostering independence.Surgical Interventions represent an impactful treatment approach for specific cases, allowing for direct intervention in progressive disorders, thereby improving outcomes. Considering the high prevalence of neurodegenerative diseases in India, these treatment modalities are not only pivotal in managing these conditions but also highlight the growing demand for specialized care.

The rising aging population and lifestyle changes are leading to an increase in the burden of these diseases, creating significant opportunities for advancements in treatment types within the India Neurodegenerative Disease Market.

**Neurodegenerative Disease Market Route of Administration Insights**

The Route of Administration segment within the India Neurodegenerative Disease Market reflects a diverse landscape, essential for effectively targeting treatment delivery to patients. Historically, oral administration has emerged as a favored choice due to its ease of use and patient compliance, making it significant in the management of chronic conditions like Alzheimer's disease. Injectable forms have gained traction for their quick delivery and effectiveness in acute scenarios, enhancing therapeutic outcomes.

Meanwhile, intravenous methods are crucial for patients needing immediate and potent medication, showcasing their importance in hospitals and specialized care frameworks.Transdermal patches present an innovative alternative, allowing for sustained drug release and minimizing gastrointestinal side effects, thus appealing to patients who prefer non-invasive options. With the landscape of healthcare evolving, the development of advanced formulations and drug delivery systems is expected to drive growth in these routes, reflecting the need for customized and patient-centric approaches in neurodegenerative disease therapies.

As India grapples with rising cases of neurodegenerative diseases, the strategic focus on these administration routes will be vital in improving treatment outcomes and patient quality of life.

**India Neurodegenerative Disease Market Key Players and Competitive Insights**

The competitive landscape of the India Neurodegenerative Disease Market is characterized by a growing focus on innovative treatment solutions, driven by increasing prevalence rates and evolving patient needs. The market encompasses a wide range of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, among others. As awareness of these conditions rises, so too does the demand for effective therapies capable of improving the quality of life for affected individuals. Companies operating in this space are increasingly investing in research and development to pioneer novel therapies, while also seeking strategic partnerships and collaborations to bolster their market position.

This dynamic environment is further propelled by advancements in biotechnology and pharmaceuticals, allowing for more targeted treatment options tailored to specific patient populations. Wockhardt has established itself as a significant player in the India Neurodegenerative Disease Market through its robust portfolio of pharmaceutical products and a commitment to research and development. The company's strengths lie in its strong manufacturing capabilities, ensuring a consistent supply of quality medications. Wockhardt's strategic focus on therapeutic areas relevant to neurodegenerative diseases, combined with its established distribution networks in India, allows it to maintain a competitive edge.

Furthermore, Wockhardt has been proactive in engaging with healthcare professionals and stakeholders, which enhances its credibility and fosters brand loyalty. The company's ability to innovate and adapt to market trends positions it as a formidable competitor in the Indian neurodegenerative sector, contributing meaningfully to the overall growth of the market.Intas Pharmaceuticals has made significant strides within the India Neurodegenerative Disease Market, offering a range of products that address various neurological conditions. Known for its commitment to quality and affordability, Intas has positioned itself as a reliable source of medications for patients and healthcare providers alike.

The company's strengths are reflected in its comprehensive pipeline of generics and specialty pharmaceuticals designed to treat neurodegenerative diseases, alongside a strong focus on research initiatives to advance therapeutic options. Intas Pharmaceuticals actively pursues mergers and acquisitions to expand its product portfolio and enhance its market presence, ensuring that it remains competitive. The firm’s collaborations with research institutions and participation in clinical trials further underscore its dedication to innovation in the neurodegenerative domain, reinforcing its status as a key player in the Indian market for these diseases.

**Key Companies in the India Neurodegenerative Disease Market Include**

- Wockhardt
- Intas Pharmaceuticals
- Dr. Reddy's Laboratories
- Sanofi India
- AbbVie
- Merck & Co.
- Biocon
- Zydus Cadila
- Pfizer
- AstraZeneca
- Novartis
- Cipla
- BristolMyers Squibb
- Sun Pharmaceutical Industries
- Eli Lilly and Company

**India Neurodegenerative Disease Market Industry Developments**

The India Neurodegenerative Disease Market has seen notable developments in recent months, particularly with major pharmaceutical companies such as Wockhardt, Dr. Reddy's Laboratories, and Biocon intensifying their focus on Research and Development for therapeutic solutions targeting diseases like Alzheimer's and Parkinson’s. In September 2023, Intas Pharmaceuticals launched a new formulation aimed at improving patient outcomes for dementia, further indicating the increasing competition within the sector. Additionally, Sanofi India reported a significant growth valuation in their neurodegenerative pipeline, which has positively influenced their market position.

There were reports of AstraZeneca entering collaborations to enhance existing therapies in October 2023, reinforcing the trend of partnership-driven innovation. Regarding mergers and acquisitions, in August 2023, Eli Lilly and Company acquired a biotech firm that specializes in neurodegenerative therapies, a move that is set to strengthen its portfolio in India. The Indian government’s initiatives to bolster healthcare infrastructure have also contributed to a favorable environment for investment and growth in this market. The sector's expansion reflects a heightened awareness and urgency surrounding neurodegenerative diseases in India, driven by an aging population and rising incidences of these conditions.

**India Neurodegenerative Disease Market Segmentation Insights**

**Neurodegenerative Disease Market Disease Type****Outlook**

- Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Amyotrophic Lateral Sclerosis
- Huntington's Disease

**Neurodegenerative Disease Market Diagnosis Method****Outlook**

- Neurological Examination
- Imaging Techniques
- Cerebrospinal Fluid Analysis
- Electrophysiological Tests

**Neurodegenerative Disease Market Treatment Type****Outlook**

- Medication
- Therapy
- Rehabilitation
- Surgical Interventions

**Neurodegenerative Disease Market Route of Administration****Outlook**

- Oral
- Injectable
- Intravenous
- Transdermal

## Market Drivers

### Growing Aging Population

The increasing aging population in India is a crucial driver for the neurodegenerative disease market. As life expectancy rises, the prevalence of age-related neurodegenerative disorders, such as Alzheimer's and Parkinson's disease, is expected to escalate. Current estimates suggest that by 2025, approximately 140 million individuals in India will be aged 60 and above, leading to a higher incidence of these diseases. This demographic shift necessitates enhanced healthcare services and innovative treatment options, thereby propelling the neurodegenerative disease market. Furthermore, the growing burden on caregivers and healthcare systems highlights the urgent need for effective interventions and support mechanisms, which could stimulate market growth. The increasing demand for specialized care facilities and home-based care solutions further indicates a significant opportunity for stakeholders in the neurodegenerative disease market.

### Increased Research Funding

Increased research funding is a pivotal driver for the neurodegenerative disease market in India. Government initiatives and private investments are focusing on understanding the underlying mechanisms of neurodegenerative disorders, which could lead to the development of novel therapies. In recent years, funding for research in neuroscience has seen a substantial rise, with allocations reaching approximately $200 million annually. This financial support is fostering collaborations between academic institutions and pharmaceutical companies, facilitating the translation of research findings into clinical applications. As a result, the neurodegenerative disease market is likely to benefit from a pipeline of innovative treatments and therapies. The emphasis on research not only enhances the understanding of these diseases but also encourages the development of preventive strategies, which could further drive market growth.

### Rising Healthcare Expenditure

India's rising healthcare expenditure is another significant driver impacting the neurodegenerative disease market. The government and private sectors are increasingly investing in healthcare infrastructure, which includes the development of specialized facilities for neurodegenerative disorders. In recent years, healthcare spending has grown to approximately 3.5% of GDP, reflecting a commitment to improving health outcomes. This financial commitment is likely to enhance access to diagnostic tools, treatment options, and rehabilitation services for patients suffering from neurodegenerative diseases. Additionally, the introduction of health insurance schemes is expected to alleviate the financial burden on families, thereby increasing the demand for neurodegenerative disease treatments. As more resources are allocated to research and development, the market is poised for growth, with innovative therapies and technologies emerging to address the needs of patients.

### Growing Patient Advocacy Groups

The emergence of patient advocacy groups is significantly influencing the neurodegenerative disease market in India. These organizations play a vital role in raising awareness about neurodegenerative disorders, promoting research, and supporting patients and their families. By advocating for better healthcare policies and funding, these groups are helping to shape the landscape of care for individuals affected by these diseases. Their efforts have led to increased public awareness, which is crucial for early diagnosis and treatment. Moreover, these organizations often collaborate with healthcare providers and researchers to facilitate access to information and resources. As the influence of patient advocacy groups continues to grow, they are likely to drive demand for improved treatment options and support services within the neurodegenerative disease market.

### Technological Advancements in Diagnostics

Technological advancements in diagnostics are transforming the neurodegenerative disease market in India. Innovations such as advanced imaging techniques, biomarker identification, and genetic testing are enhancing the accuracy of early diagnosis. These developments are crucial, as early detection can significantly improve patient outcomes and treatment efficacy. The market for diagnostic tools is projected to grow at a CAGR of around 10% over the next five years, driven by the increasing demand for precise and timely diagnosis. Furthermore, the integration of artificial intelligence and machine learning in diagnostic processes is expected to streamline workflows and reduce costs. As healthcare providers adopt these technologies, the neurodegenerative disease market is likely to expand, offering new opportunities for companies specializing in diagnostic solutions.

## Future Outlook

The [Neurodegenerative Disease Market](https://www.marketresearchfuture.com/reports/neurodegenerative-disease-market-19218) in India is poised for growth at 7.6% CAGR from 2025 to 2035, driven by increasing patient population and advancements in treatment options.

**New opportunities:**

- Development of telehealth platforms for remote patient monitoring
- Investment in AI-driven drug discovery technologies
- Expansion of personalized medicine approaches for neurodegenerative disorders

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs.

## Segment Insights

### By Disease Type: Alzheimer's Disease (Largest) vs. Parkinson's Disease (Fastest-Growing)

In the India neurodegenerative disease market, Alzheimer's Disease holds the largest share, driven by the increasing prevalence and awareness of the condition. Following closely, Parkinson's Disease is gaining significant attention and is projected to grow rapidly, outpacing other types due to advancements in treatment options and supportive care initiatives.

The growth trends in the segment are influenced by various factors including the aging population, rising healthcare expenditures, and improved diagnostic technologies. The focus on research and development for effective treatments, alongside governmental support for neurodegenerative disease awareness, is propelling the market forward. This dynamic landscape is expected to see continued growth as stakeholders prioritize innovation and patient-centered care.

Alzheimer's Disease: Dominant vs. Parkinson's Disease: Emerging

Alzheimer's Disease is the dominant force in the India neurodegenerative disease market, characterized by its significant share and established treatment frameworks. This segment benefits from ongoing research and robust patient support mechanisms. In contrast, Parkinson's Disease, while currently an emerging segment, exhibits the fastest growth due to breakthroughs in therapeutic approaches and a heightened focus on early diagnosis. The contrast between these segments highlights the need for tailored strategies that cater to distinct patient requirements, with Alzheimer's positioning itself as a well-supported market leader, while Parkinson's attracts increasing investments aimed at innovation and expanding treatment accessibility.

### By Diagnosis Method: Neurological Examination (Largest) vs. Imaging Techniques (Fastest-Growing)

In the India neurodegenerative disease market, the major share is held by the Neurological Examination, which plays a crucial role due to its simplicity and effectiveness in initial diagnosis. Imaging Techniques, while currently smaller in share, are rapidly gaining traction as technology improves, offering enhanced insights into neurodegenerative conditions.

Growth trends indicate a significant rise in the adoption of advanced Imaging Techniques driven by technological innovations and the increasing focus on early diagnosis. As healthcare infrastructure expands and more patients seek timely interventions, the neurology segment will likely witness a shift towards these innovative methods, fostering competitive dynamics within the market.

Neurological Examination (Dominant) vs. Imaging Techniques (Emerging)

The Neurological Examination remains the dominant method within the diagnosis segment, primarily due to its accessibility and established protocols in clinical practice. This method allows healthcare providers to gather critical insights efficiently, guiding further investigation. On the other hand, Imaging Techniques are emerging as a vital component of diagnosis, characterized by advanced technologies such as MRI and CT scans. They offer superior visualization of brain structures, thereby enhancing diagnostic accuracy. As awareness increases and patient demand for precise diagnoses rises, the Imaging Techniques segment is expected to expand, reflecting a shift towards more innovative diagnostic approaches.

### By Treatment Type: Medication (Largest) vs. Therapy (Fastest-Growing)

In the India neurodegenerative disease market, the treatment type segment demonstrates a diverse distribution of market share among its core components. Medication holds the largest share, benefitting from established treatment protocols and a wide array of pharmaceuticals available. Conversely, therapy, although currently smaller in terms of market share, is rapidly gaining traction as more patients seek alternative and supportive treatments alongside conventional medication, thus expanding the therapeutic options available to them.

The growth trends in the treatment type segment are primarily driven by advancements in medical research and a rising patient population. The increasing prevalence of neurodegenerative diseases has escalated the demand for innovative and effective therapies, fostering an environment ripe for the expansion of both medication and therapy. Furthermore, awareness campaigns and supportive healthcare policies are propelling the adoption of rehabilitation and surgical interventions, while therapy emerges as the fastest-growing segment due to its complementary nature in patient care.

Medication (Dominant) vs. Therapy (Emerging)

Medication remains the dominant force in the India neurodegenerative disease market, characterized by a wide range of pharmaceuticals specifically targeting various conditions such as Alzheimer's and Parkinson's disease. Its dominance can be attributed to established treatment protocols and a recognized efficacy among patients and healthcare providers alike. On the other hand, therapy is an emerging segment that is quickly gaining recognition. This includes physical therapy, occupational therapy, and psychotherapeutic interventions, which collectively enhance patient outcomes and quality of life. The integration of therapy into treatment regimens is indicative of a holistic approach to managing neurodegenerative diseases, which is becoming increasingly prioritized by healthcare professionals and patients. As more research highlights the benefits of therapy, we can expect its market share to continue to grow significantly.

### By Route of Administration: Oral (Largest) vs. Injectable (Fastest-Growing)

The India neurodegenerative disease market shows a diverse distribution among various routes of administration, with oral formulations holding the largest market share. Given their ease of use and patient compliance, oral medications dominate the landscape, making them highly preferred among patients and healthcare providers alike. On the other hand, injectable routes, while not as widely utilized, are witnessing a rapid uptake due to advances in formulations and the effectiveness in delivering active compounds directly into the bloodstream.

Growth trends for the routes of administration segment are primarily driven by innovation and the rising prevalence of neurodegenerative disorders. Injectable formulations are increasingly being adopted, particularly in scenarios where rapid therapeutic effects are desired. The market advantage of oral administration lies in its convenience, while injectables cater to specific patient needs, leading to a balanced yet competitive dynamic in the India neurodegenerative disease market.

Oral (Dominant) vs. Injectable (Emerging)

Oral administration is the dominant route of administration in the market due to its convenience and high levels of patient adherence, making it a preferred choice for chronic neurodegenerative conditions. Oral medications are often easier to self-administer and can be taken at home, which fits well within the lifestyle of many patients. Conversely, injectable routes, although traditionally viewed as less favorable due to perceived discomfort, are emerging as a significant option in managing neurodegenerative diseases, especially when rapid drug action is essential. With recent innovations improving the ease of administration and efficacy of injectables, they are positioned for growth, catering especially to patients who require more controlled dosing regimens.

## Competitive Benchmarking

The neurodegenerative disease market in India is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing aging population. Major players such as Biogen (US), Eli Lilly (US), and Roche (CH) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Biogen (US) focuses on developing novel therapies for Alzheimer's disease, while Eli Lilly (US) emphasizes its commitment to research and development, particularly in the field of amyloid-targeting therapies. Roche (CH) is actively pursuing collaborations with local biotech firms to accelerate drug development, indicating a trend towards localized innovation that shapes the competitive environment.
Key business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of key players is significant, as they drive advancements in treatment options and patient care, thereby shaping the overall market structure.
In October 2025, Biogen (US) announced a strategic partnership with a leading Indian biotech firm to co-develop a new treatment for Parkinson's disease. This collaboration is expected to leverage local expertise and resources, potentially accelerating the development timeline and enhancing market access. Such partnerships may prove crucial in navigating regulatory landscapes and addressing specific patient needs in India.
In September 2025, Eli Lilly (US) launched a new clinical trial for its innovative Alzheimer's treatment in India, aiming to recruit a diverse patient population. This initiative underscores the company's commitment to addressing the unique challenges faced by Indian patients and highlights the importance of localized clinical research in developing effective therapies. The trial's success could significantly bolster Eli Lilly's position in the market.
In August 2025, Roche (CH) expanded its operations in India by establishing a new research facility dedicated to neurodegenerative diseases. This investment reflects Roche's long-term strategy to enhance its R&D capabilities and foster innovation in the region. The facility is expected to facilitate collaboration with local researchers and institutions, potentially leading to breakthroughs in treatment options.
As of November 2025, current competitive trends in the neurodegenerative disease market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are increasingly shaping the landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve, with a shift from price-based competition to a focus on technological advancements, innovative therapies, and reliable supply chains. This transition may ultimately enhance patient outcomes and reshape the market dynamics.

## Recent News & Developments

The India Neurodegenerative Disease Market has seen notable developments in recent months, particularly with major pharmaceutical companies such as Wockhardt, Dr. Reddy's Laboratories, and Biocon intensifying their focus on Research and Development for therapeutic solutions targeting diseases like Alzheimer's and Parkinson’s. In September 2023, Intas Pharmaceuticals launched a new formulation aimed at improving patient outcomes for dementia, further indicating the increasing competition within the sector. Additionally, Sanofi India reported a significant growth valuation in their neurodegenerative pipeline, which has positively influenced their market position.

There were reports of AstraZeneca entering collaborations to enhance existing therapies in October 2023, reinforcing the trend of partnership-driven innovation. Regarding mergers and acquisitions, in August 2023, Eli Lilly and Company acquired a biotech firm that specializes in neurodegenerative therapies, a move that is set to strengthen its portfolio in India. The Indian government’s initiatives to bolster healthcare infrastructure have also contributed to a favorable environment for investment and growth in this market. The sector's expansion reflects a heightened awareness and urgency surrounding neurodegenerative diseases in India, driven by an aging population and rising incidences of these conditions.

## Report Scope

| MARKET SIZE 2024 | 4096.32(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 4407.64(USD Million) |
| MARKET SIZE 2035 | 9171.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.6% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Biogen (US), Eli Lilly (US), Roche (CH), Novartis (CH), AstraZeneca (GB), Merck (US), Amgen (US), Sanofi (FR), Bristol-Myers Squibb (US) |
| Segments Covered | Disease Type, Diagnosis Method, Treatment Type, Route of Administration |
| Key Market Opportunities | Advancements in personalized medicine and digital health technologies enhance treatment options in the neurodegenerative disease market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition in the neurodegenerative disease market amid regulatory changes. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What is the current valuation of the India neurodegenerative disease market?**
A: The market valuation was $4096.32 Million in 2024.

**Q: What is the projected market size for the India neurodegenerative disease market by 2035?**
A: The market is projected to reach $9171.0 Million by 2035.

**Q: What is the expected CAGR for the India neurodegenerative disease market during the forecast period 2025 - 2035?**
A: The expected CAGR is 7.6% during the forecast period 2025 - 2035.

**Q: Which companies are the key players in the India neurodegenerative disease market?**
A: Key players include Biogen, Eli Lilly, Roche, Novartis, AstraZeneca, Merck, Amgen, Sanofi, and Bristol-Myers Squibb.

**Q: What are the major segments of the India neurodegenerative disease market?**
A: Major segments include Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Huntington's Disease.

**Q: How much was the market size for Alzheimer's Disease in 2024?**
A: The market size for Alzheimer's Disease was $1200.0 Million in 2024.

**Q: What is the projected market size for Parkinson's Disease by 2035?**
A: The projected market size for Parkinson's Disease is $2000.0 Million by 2035.

**Q: What are the different diagnosis methods used in the India neurodegenerative disease market?**
A: Diagnosis methods include Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, and Electrophysiological Tests.

**Q: What treatment types are available in the India neurodegenerative disease market?**
A: Available treatment types include Medication, Therapy, Rehabilitation, and Surgical Interventions.

**Q: What routes of administration are utilized for treatments in the India neurodegenerative disease market?**
A: Routes of administration include Oral, Injectable, Intravenous, and Transdermal.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-neurodegenerative-disease-market-52617*